Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.1
4.9
Journals
IJMS
Special Issues
Thyroid Disease and Thyroid Cancer 2.0
ijms-logo
Submit to IJMS Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Thyroid Disease and Thyroid Cancer 2.0

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: closed (30 April 2024) | Viewed by 14360

Special Issue Editors

Prof. Dr. Artur Bossowski

E-Mail Website
Guest Editor
Department of Pediatrics, Endocrinology, Diabetology with Cardiology Unit, Medical University of Bialystok, 15-274 Bialystok, Poland
Interests: genetic pathomechanisms in autoimmune diseases; pediatric endocrinology; diabetology
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Malgorzata Gabriela Wasniewska

E-Mail Website
Guest Editor
Department of Human Pathology of Adulthood and Childhood, University of Messina, 98124 Messina, Italy
Interests: thyroid pathology in pediatric age; thyroid alterations in genetic syndrome; thyroid cancer in pediatric age; pediatric and adolescent endocrinology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The diagnostic and therapeutic pathways of thyroid diseases in children and adults are constantly evolving, favored by advances in science that offer new opportunities to the clinician. Hence, there is a need to continuous update the knowledge of endocrinologists. Moreover, there is always a certain peculiarity and specificity of thyroid pathologies for children and adults. The main objective of this Special Issue is to provide an update on the most important topics of thyroid molecular pathology, with particular attention to innovations in the field of etiopathogenesis, diagnosis and treatment of hyper- and hypothyroidism, autoimmune thyroid diseases, thyroid nodules and cancer. Moreover, the experiences with the peculiarity of thyroid molecular pathology in genetic syndromes and in chronic diseases will also be addressed. In addition, we are interested in the topic of comorbidities in autoimmune thyroid diseases and the interrelation between Graves’ and Hashimoto’s diseases.

Furthermore, another focal point is to carry out a comparison between researchers and clinicians with the aim of transferring the most recent innovations into daily practice, adopting shared lines of behavior, and thus strengthening the integration between endocrinologists, pathologists, surgeons, and nuclear medicine doctors. This will be accepted in the form of original research, systematic reviews, reviews, perspectives, clinical trials, and opinion articles. Pure clinical studies are not suitable, but clinical submissions with biomolecular studies are welcomed.

Prof. Dr. Artur Bossowski
Prof. Dr. Malgorzata Gabriela Wasniewska
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • autoimmune thyroid diseases
  • hypothyroidism
  • hyperthyroidism
  • thyroid cancer
  • immunogenetic factors
  • immune response
  • therapeutic strategy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review, Other

12 pages, 1407 KiB  
Article
Prevalence of Selected Polymorphisms of Il7R, CD226, CAPSL, and CLEC16A Genes in Children and Adolescents with Autoimmune Thyroid Diseases
by Hanna Borysewicz-Sańczyk, Natalia Wawrusiewicz-Kurylonek, Joanna Gościk, Beata Sawicka, Filip Bossowski, Domenico Corica, Tommaso Aversa, Małgorzata Waśniewska and Artur Bossowski
Int. J. Mol. Sci. 2024, 25(7), 4028; https://doi.org/10.3390/ijms25074028 - 4 Apr 2024
Cited by 1 | Viewed by 1029
Abstract
Hashimoto’s thyroiditis (HT) and Graves’ disease (GD) are common autoimmune endocrine disorders in children. Studies indicate that apart from environmental factors, genetic background significantly contributes to the development of these diseases. This study aimed to assess the prevalence of selected single-nucleotide polymorphisms (SNPs) [...] Read more.
Hashimoto’s thyroiditis (HT) and Graves’ disease (GD) are common autoimmune endocrine disorders in children. Studies indicate that apart from environmental factors, genetic background significantly contributes to the development of these diseases. This study aimed to assess the prevalence of selected single-nucleotide polymorphisms (SNPs) of Il7R, CD226, CAPSL, and CLEC16A genes in children with autoimmune thyroid diseases. We analyzed SNPs at the locus rs3194051, rs6897932 of IL7R, rs763361 of CD226, rs1010601 of CAPSL, and rs725613 of CLEC16A gene in 56 HT patients, 124 GD patients, and 156 healthy children. We observed significant differences in alleles IL7R (rs6897932) between HT males and the control group (C > T, p = 0.028) and between all GD patients and healthy children (C > T, p = 0.035) as well as GD females and controls (C > T, p = 0.018). Moreover, the C/T genotype was less frequent in GD patients at rs6897932 locus and in HT males at rs1010601 locus. The presence of the T allele in the IL7R (rs6897932) locus appears to have a protective effect against HT in males and GD in all children. Similarly, the presence of the T allele in the CAPSL locus (rs1010601) seems to reduce the risk of HT development in all patients. Full article
(This article belongs to the Special Issue Thyroid Disease and Thyroid Cancer 2.0)
►▼ Show Figures

Figure 1

Review

Jump to: Research, Other

14 pages, 1210 KiB  
Review
Promising Approaches in Plant-Based Therapies for Thyroid Cancer: An Overview of In Vitro, In Vivo, and Clinical Trial Studies
by Ilona Kaczmarzyk, Martyna Nowak-Perlak and Marta Woźniak
Int. J. Mol. Sci. 2024, 25(8), 4463; https://doi.org/10.3390/ijms25084463 - 18 Apr 2024
Viewed by 1971
Abstract
Thyroid cancer, particularly undifferentiated tumors, poses a significant challenge due to its limited response to standard therapies. The incidence of thyroid cancer, predominantly differentiated carcinomas, is on the rise globally. Anaplastic thyroid carcinoma (ATC), though rare, is highly aggressive and challenging to treat. [...] Read more.
Thyroid cancer, particularly undifferentiated tumors, poses a significant challenge due to its limited response to standard therapies. The incidence of thyroid cancer, predominantly differentiated carcinomas, is on the rise globally. Anaplastic thyroid carcinoma (ATC), though rare, is highly aggressive and challenging to treat. Therefore, this study aimed to collect data and explore alternative treatments, focusing on the efficacy of photodynamic therapy (PDT) combined with natural compounds as well as the potential role of phytochemicals, including quercetin, kaempferol, apigenin, genistein, daidzein, naringenin, hesperitin, anthocyanidins, epigallocatechin gallate (EGCG), resveratrol, ellagic acid, ferulic acid, caffeic acid, curcumin, saponins, ursolic acid, indole-3-carbinol (I3C), capsaicin, and piperine in thyroid cancer treatment. PDT, utilizing sensitizers activated by tumor-directed light, demonstrates promising specificity compared to traditional treatments. Combining PDT with natural photosensitizers, such as hypericin and genistein, enhances cytotoxicity against thyroid carcinoma cells. This literature review summarizes the current knowledge on phytochemicals and their anti-proliferative effects in in vitro and in vivo studies, emphasizing their effectiveness and mechanism of action as a novel therapeutic approach for thyroid cancers, especially those refractory to standard treatments. Full article
(This article belongs to the Special Issue Thyroid Disease and Thyroid Cancer 2.0)
►▼ Show Figures

Figure 1

Other

Jump to: Research, Review

16 pages, 928 KiB  
Systematic Review
Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review
by Catalin Vladut Ionut Feier, Razvan Constantin Vonica, Alaviana Monique Faur, Diana Raluca Streinu and Calin Muntean
Int. J. Mol. Sci. 2024, 25(8), 4346; https://doi.org/10.3390/ijms25084346 - 15 Apr 2024
Cited by 5 | Viewed by 10557
Abstract
The broadening application of glucagon-like peptide (GLP)-1 receptor agonists, specifically semaglutide (Ozempic) for the management of diabetes and obesity brings a critical need to evaluate its safety profile, considering estimates of up to 20 million prescriptions per year in the US until 2035. [...] Read more.
The broadening application of glucagon-like peptide (GLP)-1 receptor agonists, specifically semaglutide (Ozempic) for the management of diabetes and obesity brings a critical need to evaluate its safety profile, considering estimates of up to 20 million prescriptions per year in the US until 2035. This systematic review aims to assess the incidence of thyroid cancer and detail the spectrum of adverse events associated with semaglutide, focusing on its implications for patient care. Through a systematic search of PubMed, Scopus, and Embase databases up to December 2023, ten randomized controlled trials (RCTs) involving 14,550 participants, with 7830 receiving semaglutide, were analyzed, with an additional number of 18 studies that were separately discussed because they reported data from the same RCTs. The review focused on thyroid cancer incidence, gastrointestinal symptoms, and other significant adverse events attributed to semaglutide. The incidence of thyroid cancer in semaglutide-treated patients was less than 1%, suggesting no significant risk. Adverse events were predominantly gastrointestinal, including nausea (2.05% to 19.95%) and diarrhea (1.4% to 13%). Nasopharyngitis and vomiting were also notable, with mean prevalences of 8.23% and 5.97%, respectively. Other adverse events included increased lipase levels (mean of 6.5%), headaches (mean prevalence of 7.92%), decreased appetite (reported consistently at 7%), influenza symptoms (mean prevalence of 5.23%), dyspepsia (mean prevalence of 5.18%), and constipation (mean prevalence of 6.91%). Serious adverse events varied from 7% to 25.2%, highlighting the need for vigilant patient monitoring. These findings underscore the gastrointestinal nature of semaglutide’s adverse events, which, while prevalent, did not significantly deter from its clinical benefits in the treatment landscape. This systematic review provides a comprehensive assessment of semaglutide’s safety profile, with a focus on gastrointestinal adverse events and a low incidence of thyroid cancer. Despite the prevalence of gastrointestinal symptoms, semaglutide remains an efficacious option for managing diabetes and obesity. The detailed characterization of adverse events underscores the importance of monitoring and managing these effects in clinical practice, excluding the hypothesis of carcinogenesis. Full article
(This article belongs to the Special Issue Thyroid Disease and Thyroid Cancer 2.0)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop